March 2, 2026 4:42pm

Pre-open Indication Results: 4 Hits and 1 Miss

News: Intellia Therapeutics (NTLA +$1.66 or +12.05% to $15.44) the FDA has removed the clinical hold on the (IND for the MAGNITUDE P3 clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Following the observation of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in MAGNITUDE that met the trial’s protocol-defined pausing criteria.

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

Monday’s RMi Pre-opening: Incoming … https://www.regmedinvestors.com/articles/14333  

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Monday: The Dow closed DOWN -73.14 points or -0.15%, the S&P closed UP +2.74 points or +0.04% while the Nasdaq closed UP +80.646 points or +0.36%

  • Theme of the session: buying the dip

Monday’s (my) 40-company covered sector’s advance/decline line opened negative with 2 incliners, 36 decliners and 4 flats, ending with a negative close of 15 incliners, 23 decliners and 2 flats

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • Military operations reflect issues in the world’s order and its markets

The CBOE Fear (VIX) index, Monday closed at 21.42, after Friday’s 19.90, after Thursday’s 18.62, Wednesday’s 17.89, Tuesday’s 19.61 and last Monday’s 21.01

Metrics: Monday …

  • The RUT was up +23.58 points or +0.90%,
  • The XLV was down – 1.67 points or -1.04%,
  • The NBI was down -29.44 points or -0.49%;
  • The XBI was down -0.82 points or -0.64%
  • The IWM was up +2.41 or +0.92%;
  • The IBB was down -1.45 points or -0.83%,
  • The VIX was up +1.56 points or +7.84% at to 21.42

 

Q1/26 – March – 1 negative close

  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Monday Closing UP (15 of 15) +$ after Friday’s

  • Arrowhead Pharmaceuticals (ARWR +$1.06),
  • Intellia Therapeutics (NTLA +$1.66 after Friday’s -$0.50),
  • Ionis Pharmaceuticals (IONS +$0.81 after Friday’s +$0.55),
  • CRISPR Therapeutics (CRSP +$0.63 after Friday’s -$1.60),
  • Dyne Therapeutics (DYN +$0.53 after Friday’s -$0.57),
  • Supernus Therapeutics (SUPN +$0.36 after Friday’s -$1.02),
  • Beam Therapeutics (BEAM +$0.23),
  • Regenxbio (RGNX +$0.20 after Friday’s +$0.29),
  • Lenz Therapeutics (LENZ +$0.19),
  • Voyager Therapeutics (VYGR +$0.05),
  • Prime Medicine (PRME +$0.04 after Friday’s +$0.24),
  • Brainstorm Cell Therapeutics (BCLI +$0.04),
  • Compass Therapeutics (CMPX +$0.03),
  • Fate Therapeutics (FATE +$0.02),
  • Agenus (AGEN +$0.01)

Flat (2)

  • Harvard Apparatus RT (OTCQB: HRGN)
  • Generation Bio (GBIO) – acquired

Monday’s Closing DOWN (10 of 23): 

  • Vertex (VRTX -$10.80 after Friday’s +$16.70),
  • Alnylam Pharmaceuticals (ALNY -$7.85 after Friday’s +$1.68),
  • uniQure NV (QURE -$5.13 after Friday’s -$1.48),
  • IQIA Holdings (IQV -$4.54 after Friday’s +$8.28),
  • BioNTech (BNTX -$2.75 after Friday’s +$1.43),
  • BioLife Solutions (BLFS -$1.68 after Friday’s +$1.72),
  • Mesoblast (MESO -$1.34 after Friday’s -$1.07),
  • AxoGen (AXGN -$1.08),
  • Capricor Therapeutics (CAPR -$1.07 after Friday’s +$0.04)
  • Moderna (MRNA -$0.72 after Friday’s +$1.86),
  • Ultragenyx Pharmaceuticals (RARE -$0.44 after Friday’s +$0.35)

 

The Bottom Line: More of the … WHY

Boom of bombs and then the smoke as some fires abate … in markets and the C&GT sector

Indexes recovered from a considerable sell-off in early afternoon on Monday, after experiencing the fallout from US and Israeli attacks on Iran as well and subsequent counterattacks.

  • The impact on oil prices, and in turn on inflation, still remained uneasy about the backdrop for stocks. February in negative territory after renewed volatility in AI and software names rattled markets.

The next key input into those rate calculations comes Friday, with the release of the monthly jobs report.

  • Economists expect US payrolls to have added 60,000 jobs in February, down from January’s stronger-than-expected 130,000 gain that eased recession fears. <Yahoo Finance>

 

More earnings this week and coming… Earnings release dates: soon to be catching up

  • Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Rocket pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Vericel (VCEL) and BioLife Solutions (BLFS)
  • Monday - 3/2 – Dyne Therapeutics (DYN)

 

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

March – 1st week

  • 3/2 - Monday closed negative with 15 incliners, 23 decliners and 2 flats

February – 4th week

  • 2/27 – Friday closed negative with 12 incliners, 26 decliners and 2 flats
  • 2/26 – Thursday closed positive with 24 incliners, 14 decliners and 2 flats
  • 2/25 - Wednesday closed positive with 20 incliners, 19 decliners and 1 flat
  • 2/24 - Tuesday closed positive with 32 incliners, 5 decliners and 3 flats
  • 2/23 - Monday closed positive with 24 incliners, 13 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Monday: Intellia Therapeutics (NTLA), Arrowhead Pharmaceuticals (ARWR) and Ionis Pharmaceuticals (IONS)
  • Friday: Vertex (VRTX), IQIA Holdings (IQV) and Moderna (MRNA)
  • Thursday: IQIA Holdings (IQV), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY)
  • Wednesday: Supernus Therapeutics (SUPN), Moderna (MRNA) and uniQure NV (QURE)
  • Tuesday: Vertex (VRTX), Beam Therapeutics (BEAM) and Alnylam Pharmaceuticals (ALNY)  
  • Last Monday: Vertex (VRTX), Ionis Pharmaceuticals (IONS) and uniQure NV (QURE)

The worst three (3) in the session: Losers

  • Monday: Vertex (VRTX), uniQure NV (QURE) and IQIA Holdings (IQV)
  • Friday: Vericel (VCEL), CRISPR Therapeutics (CRSP) and UniQure NV (QURE)
  • Thursday: uniQure NV (QURE), Vertex (VRTX) and Sarepta Therapeutics (SRPT)
  • Wednesday: Ionis Pharmaceuticals (IONS), Vertex (VRTX) and Alnylam Pharmaceuticals (ALNY)
  • Tuesday: AxoGen (AXGN), uniQure NV (QURE), and BioLife Solutions (BLFS)
  • Last Monday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and Sarepta Therapeutics (SRPT)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.